Bupropion for the Treatment of Methamphetamine Dependence - 1 - Tabular View

Tracking Information

First Received Date ^ICMJE

September 18, 2003

Last Updated Date

July 21, 2008

Start Date ^ICMJE

July 2003

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Severity addiction
Methamphetamine use

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00069251 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Bupropion for the Treatment of Methamphetamine Dependence - 1

Official Title ^ICMJE

Bupropion for the Treatment of Methamphetamine Dependence

Brief Summary

The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence

Detailed Description

A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.

Study Phase

Phase II

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Condition ^ICMJE

Amphetamine-Related Disorders

Intervention ^ICMJE

Drug: Bupropion

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

150

Completion Date

June 2005

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis
Subject must be willing to comply with study procedures.
Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures
Be able to comply with protocol requirements

Exclusion Criteria:

Please contact site for more information.

Gender

Both

Ages

18 Years to 65 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00069251

Responsible Party

Study ID Numbers ^ICMJE

NIDA-CTO-0008-1

Study Sponsor ^ICMJE

National Institute on Drug Abuse (NIDA)

Collaborators ^ICMJE

Investigators ^ICMJE

Principal Investigator:

Richard Rawson, Ph.D.

University of California, Los Angeles

Information Provided By

National Institute on Drug Abuse (NIDA)

Verification Date

July 2008

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP